Agenus raises $52.2 million in follow-on

Agenus Inc. (NASDAQ:AGEN) raised $52.2 million through the sale of 19.3 million shares at $2.70 in a follow-on underwritten by William Blair; Maxim; H.C. Wainwright; and MLV. Agenus proposed the follow-on after market close on Tuesday, when its share price was $2.90. The company's Prophage cancer vaccines are autologous therapies derived from cells extracted from the patient's tumor. The company is evaluating the vaccines in Phase II trials in newly diagnosed and recurrent glioblastoma multiforme (GBM). Agenus' QS-21 Stimulon adjuvant is also partnered with companies, including GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). GSK's malaria vaccine RTS,S uses the AS01 adjuvant, which contains QS-21. ...